Calidi Biotherapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.11M
- P/E (TTM)
- –
- Dividend yield
- –
About Calidi Biotherapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer. The company explores proprietary delivery and expression platforms designed to utilize oncolytic viruses and cell therapies to treat various solid tumors and oncological conditions. Its operations concentrate entirely on research and development activities in the biopharmaceutical space.
The company operates in the United States, maintaining its principal executive offices in San Diego, California. It conducts administrative, research, and managerial functions from this leased commercial facility. Calidi Biotherapeutics does not operate multiple commercial branches, retail locations, or distinct regional reporting segments, concentrating its primary organizational infrastructure and executive oversight at its headquarters location in California.
Summary of the business section of Calidi Biotherapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Calidi Biotherapeutics, Inc.
- Headquarters
- San Diego, CA
- Address
- 4475 Executive Drive, Suite 200 92121
- Phone
- (858) 794-9600
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, Costa Mesa, California
Stock & identifiers
- Ticker
- CLDI
- Other tickers
- CLDWW
- Exchange
- NYSE
- IPO date
- Sep 13, 2021
- Shares outstanding
- 3M, Aug 10, 2026
- Public float
- $8.00M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-16 reverse, Jul 31, 2026; 1-for-12 reverse, Aug 5, 2025; 1-for-10 reverse, Aug 13, 2024; 1-for-10 reverse, Jul 15, 2024
- SEC CIK
- 1855485
- EIN
- 86-2967193
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Santidrian Antonio Fernandez | Chief Scientific Officer | 327,788 |
| Eric E. Poma | Chief Executive Officer | 25,000 |
| Andrew C. Jackson | Chief Financial Officer | 2,500 |
| James A. Schoeneck | Director | 84,514 |
| Alan R. Stewart | Director | 28,976 |
| Corazon (Corsee) D. Sanders | Director | – |
| Scott Leftwich | Director | 146,631 |
| George Peoples | Director | – |
| Allan Camaisa | Director | 143,664 |
Corporate history
Events identified from SEC filings